IPTACOPAN ASH UPDATE

There was no significant difference between iptacopan monotherapy and SoC for the annualized rate of MAVES Adjusted annual Arm n/N1 rate, % (95% CI) Rate ratio (95% CI)² P value² Iptacopan 1/62 0.03 (0.00, 0.25) Rate of MAVES Not estimable 0.3173 Anti-C5 SoC 0/35 0 ■ Serious TEAE of transient ischemic attack, considered by the investigator to be unrelated to iptacopan ■ The patient had a concomitant serious TEAE of sick sinus syndrome and is continuing to receive iptacopan treatment MAVE = major adverse vascular event 1. n=number of patients with at least one event, N=overall number of patients. 2. A negative binomial model was used for the comparison between treatment arms. P value is two-sided and unadjusted. TEAE = treatment-emergent adverse event. 18 IPTACOPAN ASH UPDATE | DECEMBER 13, 2022 NOVARTIS | Reimagining Medicine

View entire presentation